Assura FY2025: 17% rental growth, swung to £166m profit & became FTSE 250's first B-Corp. Strategic acquisitions, NHS focus & ethical property leadership.
This article covers information on Assura PLC.
LON:AGRAssura isn’t just ticking boxes-it’s rewriting the playbook for healthcare property investment. The specialist REIT’s FY2025 results reveal a business firing on all cylinders, combining double-digit rental growth with industry-leading ESG credentials. Let’s dissect what makes these numbers pulse.
Assura’s financials read like a case study in disciplined execution:
The portfolio’s valuation hit £3.1bn-a £391m year-on-year leap-while maintaining a robust 5.21% net initial yield.
How did they drive such stellar income growth? Three cylinders firing in unison:
This wasn’t a year of incremental tweaks-it was strategic repositioning:
August’s £500m acquisition of 14 independent hospitals wasn’t just a transaction-it was a market statement. These assets:
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
37 viewsLikes
No ratings yet
Valuers promptly marked the portfolio up 5%-validating the pricing discipline.
May’s £250m JV with Universities Superannuation Scheme showcased financial ingenuity:
Paired with £188m of disposals at 5.1% average yield, this demonstrates Assura’s capital allocation savvy.
That B-Corp certification isn’t just a badge-it’s operational DNA. Assura embedded ESG into its financial architecture:
This isn’t corporate virtue-signalling-it’s creating tangible stakeholder value while future-proofing assets.
Despite transformational deals, Assura maintains financial poise:
The £266m term loan secured for the hospital acquisition came with a savvy 4.148% fixed-rate swap-locking in certainty amid volatility.
CEO Jonathan Murphy’s prognosis is bullish, and rightly so:
With a £19.9m committed development pipeline and 20 asset enhancement projects in flight, growth isn’t speculative-it’s contracted.
Assura’s FY2025 delivers a masterclass in healthcare property investing: acquire strategic assets at sensible yields, enhance them sustainably, and finance them prudently. The B-Corp certification proves ethical operation and financial performance aren’t mutually exclusive-they’re synergistic.
The dual takeover bids circling Assura aren’t accidental. They recognise what these results confirm: this is a rare compounder with sector-leading ESG credentials, inflation-linked cashflows, and a £3bn portfolio anchoring the backbone of UK healthcare infrastructure. For investors, the prognosis remains healthy indeed.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.